Multicenter study of bleeding and thromboembolic events with durvalumab tremelimumab vs. atezolizumab and bevacizumab in advanced HCC. - Ben Khaled N; Mohr R; Jochheim LS; Zarka V; Karin M; Artusa F; Schütte JM; Himmelsbach V; Ehmer U; Böttcher K; Foerster F; Gairing SJ; et al. (JHEP reports : innovation in hepatology, 2026)